An Evaluation of Levamisole Alone or Levamisole plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon
Publication Information Expand/Collapse
PMid: PMID28586789; PMC5710507
Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328
The Southwest Oncology Group: progress in cancer research [PMID18929152]
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients
Clinical correlation for colorectal cancers with microsatellite instability (MSI)
Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection.
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report.
The Intergroup Study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
Recognition and salvage of the patient with recurrent colon cancer.
Testing against ordered alternatives for censored survival data.
An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy
The Intergroup study of fluorouracil (5-FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report.
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma.